GZERO Media logo

Vaccine diplomacy: China in the Global South

Art by Gabriella Turrisi

As Western countries began rolling out COVID-19 vaccines last week, the UAE became the first nation to authorize use of one of China's vaccines against the coronavirus. Beijing promises a major breakthrough towards ending the pandemic for billions of people across the developing world, but it comes with risks for China, and strings attached for its customers.


First, the good news. According to the Emiratis, China's Sinopharm vaccine is 86 percent effective, slightly less than Pfizer's and Moderna's but more than expected just weeks ago. It's relatively cheap to make and only requires refrigeration, a game-changer for developing nations that lack large-scale cold-storage facilities.

Chinese vaccine makers are looking at a revenue windfall, and poor nations that may soon be able to quickly inoculate large numbers of people won't have to wait as long as they feared to begin to rebuild their economies.

Now the bad news. Chinese officials have largely contained the coronavirus at home and don't need to immediately vaccinate as big a percentage of its citizens as the US does to return to normalcy. But they will need to find the right division of supplies between 1.4 billion Chinese and the foreign countries that Chinese companies have agreed to supply. A fresh COVID-19 outbreak inside China without full domestic immunization could deal President Xi Jinping a heavy political blow.

Indeed, logistics is a big problem. Sinopharm claims it can produce up to 1 billion doses — enough to inoculate 500 million people with two doses each — in 2021. China has four other vaccine candidates in phase III clinical trials and could technically ramp up production to more than 3 billion doses next year, but it will prioritize certain countries in Southeast Asia, Africa, and Latin America.

Then there are concerns over safety. Chinese firms haven't been as forthcoming with data on their clinical trials as their Western rivals in the global vaccine race. That doesn't mean their products are unsafe, but some countries that have agreed to test them on their own citizens are wary about the lack of transparency. If the results are less than promised or vaccinations produce serious side-effects, everybody loses.

China has much to gain from its vaccine diplomacy efforts. A successful drug could do a lot to restore global faith in China, whose reputation has been severely damaged by its cover-up of the initial COVID-19 outbreak in Wuhan. Beijing says it's offering its medicine to poor countries as a "public good" with soft loans to purchase vaccines. Meanwhile, the West is engaging in "vaccine nationalism" by inoculating their own people first and selling (most of) the rest for profit.

On the other hand, China's vaccine diplomacy targets neither the US nor Western countries. Its goal is to supply the Global South, where Beijing can exercise its "soft power" by giving developing nations access to the drugs that only 20 percent of their people would receive by the end of next year under the international COVAX Facility to ensure equitable distribution of vaccines.

However, all this largesse may come with a catch. Countless recipients of Chinese loans have fallen deep into China's debt trap. If they default, a state-owned Chinese company may take over strategic infrastructure. With the vaccines, however, Beijing has learned its lesson after suffering a backlash over its ham-fisted "PPE diplomacy" at the onset of the pandemic.

With vaccines, China is unlikely to make the ties too explicit, but will expect countries to scratch their back too by being friendly to Chinese interests, or at least not overly hostile on sensitive political issues. This is now evident in Turkey — which is already turning a blind eye to China's treatment of its fellow Turkic Uighurs in China's Xinjiang region in order to get early access to Sinovac's drug — and Indonesia, another country undergoing Sinovac clinical trials that has toned down its criticisms of China's claim to the contested South China Sea.

At the end of the day, though, developing countries don't have much choice. Many can't wait until all rich countries inoculate their way to herd immunity, and will roll the dice on a Chinese vaccine that may not be as effective or safe, but will offer some quick public health and economic relief. The full price of this option will become clear over time.

Khant Thaw Htoo is a young engineer who works in Eni's Sakura Tower office in the heart of Yangon. As an HSE engineer, he monitors the safety and environmental impact of onshore and offshore operations. He also looks out for his parents' well-being, in keeping with Myanmar's traditions.

Learn more about Khant in the final episode of the Faces of Eni series, which focuses on Eni's employees around the world.

On his first day as president, Joe Biden signed a remarkable series of executive orders. Boom! The US rejoins the Paris Climate Accord. Bang! The United States rejoins the World Health Organization. Pow! No more ban on immigration from many Muslim-majority countries. Biden's press secretary reminded reporters later in the day that all these orders merely begin complex processes that take time, but the impact is still dramatic.

If you lead a country allied with the US, or you're simply hoping for some specific commitment or clear and credible statement of purpose from the US government, you might feel a little dizzy today. The sight of an American president (Barack Obama) signing his name, of the next president (Donald Trump) erasing that name from the same legislation/bill, and then the following president (Biden) signing it back into law again will raise deep concerns over the long-term reliability of the world's still-most-powerful nation.

More Show less

Ian Bremmer discusses the World In (more than) 60 Seconds:

Biden's first scheduled call with a world leader will be with Canada's Justin Trudeau. What's going on with the Keystone Pipeline?

Well, Biden said that that's it. Executive order, one of the first is that he will stop any construction or development of the Keystone Pipeline. This is of course an oil pipeline that would allow further oil sands oil to come to the United States. The infrastructure is significantly overstretched, it's led to backlogs, inefficiency, accidents, all the rest, but it also facilitates more energy development and keeps prices comparatively down if you get it done. So, there are lots of reasons why the energy sector in Canada wants it. Having said all of that, Trudeau, even though he's been a supporter of Keystone XL, let's keep in mind that he did not win support in Alberta, which is where the big energy patch in Canada is located. This is a real problem for the government of Alberta, Canada is a very decentralized federal government, even more so than the United States. The premier of Alberta is immensely unhappy with Biden right now, they've taken a $1.5 billion equity stake in the project. I expect there will actually be litigation against the United States by the government of Alberta. But Trudeau is quite happy with Biden, his relationship was Trump was always walking on eggshells. The USMCA in negotiations ultimately successful but were very challenging for the Canadians, so too with the way Trump engaged in relations on China. All of this, the fact that Trump left the nuclear agreement with Iran, the Paris Climate Accords, WHO, all of that is stuff that Trudeau strongly opposed. He's going to be much more comfortable with this relationship. He's delighted that the first call from Biden is to him. And it certainly creates a level of normalcy in the US-Canada relationship that is very much appreciated by our neighbors to the North.

More Show less

Kevin Sneader, Global Managing Partner at McKinsey & Company, provides perspective on what corporate business leaders are thinking during the global coronavirus crisis:

Should businesses be pessimistic or optimistic about 2021?

It's easy to be gloomy about the year ahead when faced with the realities of a cold, bleak winter in much of the world. Add to that lockdowns across Europe, surging case numbers and hospitalizations, and dreadful events in the Capitol in the US to name a few reasons for pessimism. But I think there is a case for optimism when it comes to this year. After all, it's true to say that it's always darkest before the dawn, and my conversations with business leaders suggest there are reasons to be positive by 2021.

More Show less

Renowned tech journalist Kara Swisher has no qualms about saying that many of the country's social media companies need to be held accountable for their negative role in our current national discourse. Swisher calls for "a less friendly relationship with tech" by the Biden administration, an "internet bill of rights" around privacy, and an investigation into antitrust issues.

Swisher, who hosts the New York Times podcast Sway, joins Ian Bremmer for the latest episode of GZERO World, airing on public television nationwide beginning this Friday, January 22th. Check local listings.

The GZERO World Podcast with Ian Bremmer. Listen now.

GZEROMEDIA

Subscribe to GZERO Media's Newsletter: Signal